Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] ≥7 and ≤10%) with metformin alone. RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19–78 years, with mild to moderate hyperglycemia (mean A1C 8.0%) receiving ongoing metformin (≥1,500 mg/day) were randomly assigned to receive the addition of placebo or sitagliptin 100 mg once-daily in a 1:2 ratio for 24 weeks. Patients exceeding specific glycemic limits were provided rescue therapy (pioglitazone) until the end of the study. The efficacy analyses were based on an all-patients-treated population using an ANCOVA and excluded data obtained after glycemic rescue. RESULTS—At week 24, sitagliptin treatment led to significant reductions compared with placebo in A1C (−0.65%), fasting plasma glucose, and 2-h postmeal glucose. Fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio, postmeal insulin and C-peptide areas under the curve (AUCs), postmeal insulin AUC–to–glucose AUC ratio, homeostasis model assessment of β-cell function, and quantitative insulin sensitivity check index were significantly improved with sitagliptin relative to placebo. A significantly greater proportion of patients achieved an A1C <7% with sitagliptin (47.0%) than with placebo (18.3%). There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo. Body weight decreased similarly with sitagliptin and placebo. CONCLUSIONS—Sitagliptin 100 mg once-daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, studies report an increased incidence of nasopharyngitis in subjects randomly assigned to DPPIV inhibitor 35,38,40 ; in 1 study, 1 of 175 sitagliptin-treated subjects was hospitalized for angioedema.41”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [40]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 609
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Cited by
Items 301–400 of 785
Campbell, R. K., & White, J. R. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708317870 · Cited by 34
Singh, A.-K., Jatwa, R., Purohit, A., & Ram, H. (2017) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2017.1307183 · Cited by 29
Incretin Therapy – Present and Future
Garber, A. J. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.307 · Cited by 31
Gliptins: a new class of oral hypoglycaemic agent
Chahal, H., & Chowdhury, T. A. (2007) · QJM · doi:10.1093/qjmed/hcm081 · Cited by 30
Can Newer Therapies Delay the Progression of Type 2 Diabetes Mellitus?
Horton, E. S. (2008) · Endocrine Practice · doi:10.4158/ep.14.5.625 · Cited by 31
Hanefeld, M. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000225 · Cited by 28
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Zhang, Z., Yan, X., Wu, C., Pei, X., Li, X., Wang, X., Niu, X., Jiang, H., Zeng, X., & Zhou, Z. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3298 · Cited by 36
Migoya, E. M., Miller, J., Gutierrez, M., Zheng, W., Johnson‐Levonas, A. O., Liu, Q., Matthews, C. Z., Wagner, J. A., & Gottesdiener, K. M. (2010) · Clinical Drug Investigation · doi:10.1007/bf03256914 · Cited by 27
Sitagliptin for Type 2 diabetes: a 2015 update
Lee, M., & Rhee, M. K. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1046840 · Cited by 34
Ekholm, E., Hansen, L., JOHNSSON, E. K., Iqbal, N., Carlsson, B., Chen, H., & Hirshberg, B. (2016) · Endocrine Practice · doi:10.4158/ep161323.or · Cited by 27
Sharma, M., Beckley‐Hoelscher, N., Nazareth, I., & Petersen, I. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017260 · Cited by 28
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies
Penfornis, A., Borot, S., & Raccah, D. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73399-8 · Cited by 30
Halimi, S. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70309-9 · Cited by 27
Drug-induced chronic cough and the possible mechanism of action
Ding, H., Shi, C., Xu, X., & Yu, L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-819 · Cited by 31
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
Gerrald, K. R., Scoyoc, E. V., Wines, R., Runge, T. M., & Jonas, D. E. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01540.x · Cited by 27
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.10.1705 · Cited by 25
Liraglutide for the Treatment of Type 2 Diabetes: A Clinical Update
Peters, K. R. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182204c16 · Cited by 25
Sitagliptin/Metformin Fixed-Dose Combination: In Patients with Type 2 Diabetes Mellitus
Chwieduk, C. M. (2011) · Drugs · doi:10.2165/11206060-000000000-00000 · Cited by 29
Newly Approved and Promising Antidiabetic Agents
Combettes, M., & Kargar, C. (2007) · Therapies · doi:10.2515/therapie:2007054 · Cited by 27
for the JAMP Study Investigators, Sakura, H., Hashimoto, N., Sasamoto, K., Ohashi, H., Hasumi, S., Ujihara, N., Kasahara, T., Tomonaga, O., Nunome, H., et al. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0149-z · Cited by 27
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
Raskin, P. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00907.x · Cited by 24
Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue
Retterstøl, K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903164205 · Cited by 24
Mize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors
Mu, Y., Misra, A., Adam, J. M. F., Chan, S. P., Chow, F. C. C., Cunanan, E. C., Deerochanawong, C., Jang, H. C., Khue, N. T., Sheu, W. H., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.09.023 · Cited by 25
Shankar, R. R., Xu, L., Golm, G. T., O’Neill, E. A., Goldstein, B. J., Kaufman, K. D., & Engel, S. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12607 · Cited by 28
Kadowaki, T., Tajima, N., Odawara, M., Nishii, M., Taniguchi, T., & Ferreira, J. C. A. (2012) · Journal of Diabetes Investigation · doi:10.1111/jdi.12001 · Cited by 24
Han, S. J., Choi, S., KANG, Y. Y., Jung, J. G., Yi, S., Kim, H. J., Lee, K. W., & Kim, D. J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.016 · Cited by 28
Shin, D., Cho, Y. M., Lee, S., Lim, K. S., Kim, J.-A., Ahn, J.-Y., Cho, J., Lee, H., Jang, I., & Yu, K. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0184-3 · Cited by 24
Kadowaki, T., Tajima, N., Odawara, M., Minamide, T., Kawashima, M., Yanagida, D., Okamoto, T., & Ferreira, J. C. A. (2013) · Diabetology International · doi:10.1007/s13340-013-0109-z · Cited by 27
Chakraborty, C., Hsu, M. J., & Agoramoorthy, G. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-9998-0 · Cited by 27
Reimer, R. A., Grover, G. J., Koetzner, L., Gahler, R. J., Juneja, P., Lyon, M. R., & Wood, S. (2012) · Journal of Nutrition · doi:10.3945/jn.112.163204 · Cited by 27
Ku, E. J., Jung, K. Y., Kim, Y. J., Kim, K. M., Moon, J. H., Choi, S. H., Cho, Y. M., Park, K. S., Jang, H. C., Lim, S. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129477 · Cited by 31
Chao, C., Wang, J., Wu, H., Chien, K., & Hung, K. (2017) · Oncotarget · doi:10.18632/oncotarget.18081 · Cited by 27
Enhancing pediatric clinical trial feasibility through the use of Bayesian statistics
Huff, R. A., Maca, J. D., Puri, M., & Seltzer, E. W. (2017) · Pediatric Research · doi:10.1038/pr.2017.163 · Cited by 27
Zhang, T., & Maekawa, H. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b03302 · Cited by 24
A Bibliometrics Analysis of Metformin Development From 1980 to 2019
Song, Y., Ma, P., Gao, Y., Xiao, P., Xu, L., & Liu, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.645810 · Cited by 27
Sitagliptin: A novel agent for the management of type 2 diabetes mellitus
Pham, D. Q., Nogid, A., & Plakogiannis, R. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070248 · Cited by 28
Nauck, M. A., & Smith, U. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.002 · Cited by 30
de Wit, H. M., Groen, M. T., Rovers, M. M., & Tack, C. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12925 · Cited by 29
Kashiwagi, A., Kadowaki, T., Tajima, N., Nonaka, K., Taniguchi, T., Nishii, M., Ferreira, J. C. A., & Amatruda, J. M. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00120.x · Cited by 27
Yanai, H. (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr975w · Cited by 25
Cobble, M. E. (2012) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-4-8 · Cited by 26
Elevated Hepatic Enzymes Potentially Associated with Sitagliptin
Gross, B., Cross, L. B., Foard, J. C., & Wood, Y. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m323 · Cited by 23
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
Horowitz, M. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4975 · Cited by 25
Exploring Treatment Strategies for Type 2 Diabetes
Bloomgarden, Z. T. (2007) · Diabetes Care · doi:10.2337/dc07-zb10 · Cited by 26
George, R. E., & Joseph, S. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.05.005 · Cited by 23
New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals
Wysham, C. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2142 · Cited by 23
Lee, Y. K., Song, S. O., Kim, K. J., Cho, Y., Choi, Y., Yun, Y., Lee, B., Kang, E. S., Soo, B., & Lee, H. C. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.6.465 · Cited by 24
Chen, H., Zhou, X., Chen, T., Liu, B., Jin, W., Gu, H., Hong, T., & Zhang, G. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0198-3 · Cited by 24
Suthakaran, C., Kishore, U., Anjana, R. M., Unnikrishnan, R., & Mohan, V. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0120 · Cited by 24
Tajima, N., Kadowaki, T., Okamoto, T., Sato, A., Okuyama, K., Minamide, T., & Ferreira, J. C. A. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12116 · Cited by 26
Chapell, R., Gould, A. L., & Alexander, C. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01084.x · Cited by 26
Incretin-Based Therapy and Type 2 Diabetes
Hare, K. J., & Knop, F. K. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00015-1 · Cited by 24
Incretin-based therapies in type 2 diabetes: A review of clinical results
Bosi, E., Lucotti, P., Setola, E., Monti, L. D., & Piatti, P. M. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.10.003 · Cited by 27
Waters, S. B., Topp, B. G., Siler, S. Q., & Alexander, C. M. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300108 · Cited by 22
Dar, S. H., Siddiqi, A. K., Alabduladhem, T. O., Rashid, A. M., Sarfraz, S., Maniya, M. T., Menezes, R. G., & Almas, T. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103633 · Cited by 24
Green, J. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6270 · Cited by 22
Chien, M.-N., Lee, C., Chen, W.-C., Liu, S.-C., Leung, C.-H., & Wang, C. (2011) · International journal of gerontology · doi:10.1016/j.ijge.2011.04.015 · Cited by 22
Davidson, J. A., Parente, E. B., & Gross, J. L. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000600016 · Cited by 29
Bryson, A. L., Jennings, P. E., Deak, L., Paveliu, F., & Lawson, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1190334 · Cited by 25
Beyond Metformin: Initiating Combination Therapy in Patients with Type 2 Diabetes Mellitus
Goldman, J. D. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.44s · Cited by 23
Hong, A.-R., Lee, J., Ku, E. J., Hwangbo, Y., Kim, K. M., Moon, J. H., Choi, S. H., Jang, H. C., & Lim, S. K. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.019 · Cited by 21
Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes
Παπάνας, Ν., & Maltezos, E. S. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1085 · Cited by 23
Kubota, A., Matsuba, I., Saito, T., Nabe, K., & Seino, Y. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00109.x · Cited by 20
Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor
Goldsmith, F., Keenan, M. J., Raggio, A. M., Ye, X., Hao, Z., Durham, H. A., Geaghan, J. P., Jia, W., Martin, R. J., & Ye, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126177 · Cited by 23
Peng, Y. H., Chang, Q., Yang, N., Gu, S., Zhou, Y., Yin, L., Aa, J., Wang, G., & Sun, J. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.02.007 · Cited by 20
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate
Charoo, N. A., Abdallah, D. B., Abdelgader, A., Haque, K. U., Hassan, H. A., Abrahamsson, B., Cristofoletti, R., Langguth, P., Mehta, M., Parr, A. F., et al. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.09.031 · Cited by 28
Diabetes: glycaemic control in type 2 (drug treatments).
Gorter, K. J., de Laar, F. A. V., Janssen, P. G. H., Houweling, S. T., & Rutten, G. E. H. M. (2012) · Europe PMC (PubMed Central) · Cited by 20
Liraglutide in oral antidiabetic drug combination therapy
Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01574.x · Cited by 20
A 74-Year-Old Woman With Diabetes
Abrahamson, M. J. (2007) · JAMA · doi:10.1001/jama.297.2.196 · Cited by 21
Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy
Derosa, G., D’Angelo, A., & Maffioli, P. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.019 · Cited by 25
Yokoh, H., Kobayashi, K., Sato, Y., Takemoto, M., Uchida, D., Kanatsuka, A., Kuribayashi, N., Terano, T., Hashimoto, N., Sakurai, K., et al. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12282 · Cited by 20
Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
Jellinger, P. S. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2245 · Cited by 21
Fonseca, V. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.005 · Cited by 19
Add-on therapies to metformin for type 2 diabetes
Shomali, M. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.542150 · Cited by 19
Stephens, J. W., Anderson, R., & Hayes, J. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s93076 · Cited by 19
Jia, S., Wang, Z., Han, R., Zhang, Z., Li, Y., Qin, X., Zhao, M., Xiang, R., & Yang, J. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01542-4 · Cited by 18
The increasing epidemiology of diabetes and review of current treatment algorithms.
Freeman, J. S. (2010) · PubMed · Cited by 18
Approaches to Treatment of Type 2 Diabetes
Bloomgarden, Z. T. (2008) · Diabetes Care · doi:10.2337/dc08-zb08 · Cited by 23
Misumi, Y., & Ikehara, Y. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00745-6 · Cited by 20
Bennett, W. L., Balfe, L. M., & Faysal, J. M. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s1-a.1 · Cited by 17
Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes
Karyekar, C. S., Donovan, M., Allen, E., Fleming, D., Ravichandran, S., & Chen, R. K. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2305 · Cited by 17
Hypoglycemia - Causes and Occurrences
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/864 · Cited by 17
Ballav, C., & Gough, S. C. L. (2013) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7314 · Cited by 24
Approaches to Help People With Diabetes Overcome Barriers for Improved Health Outcomes
Siminerio, L. M. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721707313938 · Cited by 18
Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm
Green, J., & Feinglos, M. N. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01438.x · Cited by 20
Janumet™: a combination product suitable for use in patients with Type 2 diabetes
Reynolds, J. K., Neumiller, J. J., & Campbell, R. K. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1559 · Cited by 18
Weber, A. E., & Thornberry, N. A. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42007-3 · Cited by 21
McDonnell, M. E. (2007) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/01.hcr.0000281762.29287.a6 · Cited by 17
Cai, B., Katz, L., Alexander, C. M., Williams‐Herman, D., & Girman, C. J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02516.x · Cited by 16
Management of type 2 diabetes in the obese patient: current concerns and emerging therapies
Krentz, A. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x219661 · Cited by 17
Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
Ohmura, H., Mita, T., Taneda, Y., Sugawara, M., Funayama, H., Matsuoka, J., Watada, H., & Daida, H. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr1983w · Cited by 17
Lally, J., Loughlin, A. O., Stubbs, B., Guérandel, A., O'Shea, D. B., & Gaughran, F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445968 · Cited by 18
The incretin system and cardiometabolic disease
Szmitko, P. E., Leiter, L. A., & Verma, S. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70010-6 · Cited by 18
Shankar, R. R., Inzucchi, S. E., Scarabello, V., Gantz, I., Kaufman, K. D., Lai, E., Ceesay, P., Suryawanshi, S., & Engel, S. S. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335637 · Cited by 16
Fraser, I. P., Neufeld, N. D., Fox, L. A., Kipnes, M. S., Miller, T. L., Zeitler, P. S., Rodriguez, H., Gilmartin, J., Lee, S. H., Patterson, J. K., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12790 · Cited by 16
McGill, J. B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.01.1954 · Cited by 17
Therapeutic Potential of Dipeptidyl Peptidase-IV Inhibitors in Patients With Diabetes Mellitus
Moore, K. B., & Saudek, C. D. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180ed42dc · Cited by 15
Metadata
- Authors
- Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Sheba Medical Center (IL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 2638-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2171512247
- Cited by
- 790
- References
- 12
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 19 · 2020: 19 · 2019: 15 · 2018: 12 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 47 · 2013: 48 · 2012: 47
- FWCI
- 60.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sitagliptin, DPP-4 inhibitors, metformin, type 2 diabetes, inadequate glycemic control, HbA1c, pioglitazone, insulin sensitivity, beta-cell function, hypoglycemia, gastrointestinal adverse effects, body weight
- MeSH terms
- Sitagliptin Phosphate, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycoproteins, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Placebos, Proinsulin, Protease Inhibitors, Pyrazines, Triazoles, Single-Blind Method, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Adenosine Deaminase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.